Bivalirudin

FDA approved

Bivalirudin (Angiomax) is a 20-amino acid direct thrombin inhibitor approved by the FDA in 2000. It is used as a blood thinner during coronary angioplasty and stenting (PCI).

At a glance

Where it acts: Heart & blood
Regulatory status: FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Bivalirudin is a synthetic analog of hirudin, the anticoagulant from leeches. It binds directly and reversibly to thrombin's active site, blocking its ability to turn fibrinogen into fibrin and activate platelets, so clots cannot form.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

Bleeding, back pain, nausea, low blood pressure and headache.

Major bleeding. Short half-life means effects wear off quickly once stopped, but there is no specific reversal agent.

Who Uses Bivalirudin

Adults undergoing percutaneous coronary intervention, including those with heparin-induced thrombocytopenia.